全球绝经后阴道萎缩治疗市场 – 行业趋势及 2030 年预测

绝经后阴道萎缩治疗市场分析及规模

通过零售药店销售的绝经后阴道治疗药物（包括雌激素类药物）数量不断增加，将增强绝经后阴道萎缩治疗市场。市场上有许多品牌和仿制药，用于治疗绝经后阴道萎缩。近年来，顶级先进治疗方法的发展也帮助市场加快了步伐。除此之外，医疗改革的完善以满足阴道萎缩治疗的要求也是推动市场发展的主要因素。

Data Bridge Market Research 分析了 2023-2030 年预测期内绝经后阴道萎缩治疗市场的增长率。在上述预测期内，绝经后阴道萎缩治疗市场的预期复合年增长率趋于 7.50% 左右。2022 年市场价值为 25.2 亿美元，到 2030 年将增长至 45 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

绝经后阴道萎缩治疗市场范围和细分

Market Definition

Postmenopausal vaginal atrophy is the kind of condition of vaginal wall thinning which is caused by a decreased level of estrogen. The varied changes in the genitourinary tract initiating from a hypoestrogenic state includes reduced vaginal lubrication, thinning of the vaginal epithelium and decreased vaginal vascularization. Continuously pH increases and loss of lactobacilli microflora enables opportunistic colonization by pathogenic bacteria; this can produce infection.

Postmenopausal Vaginal Atrophy Treatment Market Dynamics

Drivers

• Incidence of Postmenopausal Vaginal Atrophy

The growing incidence of postmenopausal vaginal atrophy is increasing the demand for treatment methods. The most visible symptom is vaginal dryness which is affecting around 60% of women in the postmenopausal period. In general, these symptoms can cause sexual dysfunction and consequently lead to reduced quality of life. Thus, this factor increases the market growth.

• Increasing Healthcare Plans

Various established healthcare infrastructures, the increased frequency of disease, and the incidence of major manufacturers are the main factors leading to the market share. For instance, The Affordable Care Act has increased the number of insured women and has been a major factor in the treatment-seeking behavior of people suffering from this condition. Additionally, this law offers many U.S. citizens better health security by providing comprehensive health insurance reforms that not only have reduced health care costs but also enhance coverage. Therefore, the launch of beneficial healthcare plans in the U.S. will influence more women to seek treatment, thus helping in the growth of this market during the forecast period 2023-2030.

Opportunities

• Increased Utilization of Vaginal Tablets

Postmenopausal vaginal atrophy may result in symptoms of urogenital atrophy. The launch of the ultra-low-dose 10-µg estradiol vaginal tablets correlates with the needs of regulatory agencies and women's health societies associated with applying the least efficient hormonal dose. The 10-µg estradiol vaginal tablet may offer better reassurance to healthcare providers and postmenopausal women because of its efficiency, safety profiles, and minimal systemic absorption, with an annual estradiol administration of only 1.14 mg. Thus, this factor significantly increases the market growth.

• Increasing Demand of Estrogen Based Drugs

The increasing demand of estrogen-based drugs contributes in leading the market growth. This growth is due to the increasing application of estrogen-based drugs used for the treatment of postmenopausal vaginal atrophy among women. Systemic estrogen treatments includes creams, vaginal gels and patches. The huge application of topical estrogen therapy in the management of postmenopausal vaginal atrophy is boosting the growth of the market. These treatment methods are highly applicable in treating diseases such as hot flashes, urogenital atrophy and others.

 Restraints/Challenges

• Lack of Awareness About The Infection

The lack of awareness about these infections could reduce the growth of the global postmenopausal vaginal atrophy treatment market during the forecast period 2023-2030. Not much awareness about the infection leads to improper treatment in several underdeveloped and developing countries thus restraining the market growth.

• Adverse Effects of Vaginal Gels

There are several adverse effects associated with the treatment types of postmenopausal vaginal atrophy. Metronidazole Vaginal Gel is the intravaginal dosage form of the synthetic antibacterial agent, metronidazole, USP at a concentration of 0.75%. Vaginal gels such as Metrogel have few side effects. Metrogel – vaginal gel with applicator can have side effects such as headache, stomach discomfort, or dizziness. Vaginal discomfort or itching and may be discharge may occur or worsen. These symptoms may happen because of new vaginal infection such as yeast or fungal infection. In case of symptoms associated with severe allergic reaction which involves serious dizziness, medical assistance is required immediately. Thus, all these side-effects lead to the drop in usage of vaginal gels or drugs and which in turn decrease the market growth.

This postmenopausal vaginal atrophy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the postmenopausal vaginal atrophy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Treatment Market             

The COVID-19 pandemic has resulted in the hindrance of the development, production, and supply of drugs and other healthcare products and majorly affected the growth of healthcare businesses of many companies globally. Though, in the post-pandemic era, the market is anticipated to grow due to a major increase in R&D initiatives for exact diagnosis. Several government and non-government bodies, including the European Institute of Women's Health (EIWH) and the World Health Organization, have launched many public awareness campaigns about women's health. Therefore, COVID-19 had a major impact on the global postmenopausal vaginal atrophy treatment market.

Recent Developments

• In 2022, Novo Nordisk India launched a first-of-its-kind diabetes treatment medicine in the nation. The firm pronounced that it had launched the world's earliest and only oral semaglutide. It is developed in oral form for the first time.
• In 2021, Pfizer Inc. announced that it acquired Amplyx Pharmaceuticals, Inc. Amplyx’s lead compound, Fosmanogepix (APX001). Fosmanogepix (APX001) is a novel investigational resource under development used for the treatment of invasive fungal infections.
• In 2020, Upsher-Smith Laboratories, LLC announced that it enlarged its generic portfolio with the launch of three novel products. The products were Haloperidol Tablets, USP Fluvoxamine Maleate Tablets, and Clonidine Hydrochloride Extended-release Tablets.

Global Postmenopausal Vaginal Atrophy Treatment Market Scope

The postmenopausal vaginal atrophy treatment market is segmented on the basis of therapy type, drug form, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy Type

• Estrogen based drugs
• Non-estrogen based drugs
• Others

Drug Form

• Vaginal gel
• Creams
• Tablet
• Others

Route of Administration

• Oral
• Intravaginal
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• 零售药店

绝经后阴道萎缩治疗市场区域分析/见解

对绝经后阴道萎缩治疗市场进行了分析，并根据上述治疗类型、药物形式、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

绝经后阴道萎缩治疗市场报告涉及的主要国家 有北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于政府和制药组织采取越来越多的举措来传播认识并增加女性阴道感染的发病率，在整个预测期内，亚太地区的绝经后阴道萎缩治疗市场一直呈现积极增长态势。

北美占据了市场主导地位，因为制药组织不断采取主动措施，生产新配方，并在最终用户中广泛传播抗感染药物的意识。 

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球绝经后阴道萎缩治疗市场份额分析

绝经后阴道萎缩治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司重点关注的绝经后阴道萎缩治疗市场有关。

绝经后阴道萎缩治疗市场的主要参与者包括：

• 辉瑞公司 (美国)
• Mylan NV（美国）
• 诺华公司（瑞士）
• Hikma Pharmaceuticals plc（英国）
• Aurobindo Pharma（印度）
• AbbVie Inc.（美国）
• Melinta Therapeutics, Inc（美国）
• 百时美施贵宝公司 (美国)
• 葛兰素史克公司（英国）
• 拜耳公司（德国）
• 鲁冰花（印度）
• Perrigo Company plc（美国）
• Bionovo, Inc.（沙特阿拉伯）
• TherapeuticsMD, Inc.（美国）
• Endoceutics, Inc（加拿大）
• Upsher-Smith Laboratories, LLC（美国）
• Ligand Pharmaceuticals Incorporated（美国）
• Pantarhei Bioscience（荷兰）

SKU-52889